Ushbu ishga iqtibos qilgan ishlar

4 ta ish

Ish: Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   MaqolaCAR-T cell therapy researchClinical & Translational Oncology20261 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.000172

2. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

3. Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance

   Omer Qutaiba B. Allela, Abdulkareem Shareef, S. Renuka Jyothi +9

   MaqolaCAR-T cell therapy researchDiscover Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.001466

4. Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCAR-T cell therapy researchDiscover Oncology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.005310